Platelet activating factor
Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
Cross Reference
Introduction
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Platelet activating factor?
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
PubChem Associated disorders and diseases
What pathways are associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Platelet activating factor?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Platelet activating factor?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Platelet activating factor?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with Platelet activating factor?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Platelet activating factor?
Knock-out
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with Platelet activating factor
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Rink TJ | Stimulus-response coupling mechanisms in human platelets. | 1986 | Agents Actions Suppl. | pmid:3028101 |
| Baroggi N et al. | Changes in cytosolic free calcium induced by platelet-activating factor in rabbit platelets: specific inhibition by BN 52021 and structurally related compounds. | 1986 | Agents Actions Suppl. | pmid:3028108 |
| Bertrand C et al. | Selective implication of thromboxane A2 and PAF-acether in two guinea pig anaphylactic models. | 1990 | Agents Actions Suppl. | pmid:2080755 |
| Tsunoda H et al. | Effects of a novel PAF antagonist, E6123, on PAF-induced biological responses. | 1990 | Agents Actions Suppl. | pmid:2080757 |
| Sakuma Y et al. | Effects of a novel PAF antagonist, E6123, on passive anaphylaxis. | 1990 | Agents Actions Suppl. | pmid:2080758 |
| Parnham MJ et al. | Regulation of the oxidative burst of macrophages by lipid mediators. | 1984 | Agents Actions Suppl. | pmid:6433680 |
| Schrör K and Felsch A | Ramiprilat prevents PAF-induced myocellular and endothelial injury in a neutrophil-perfused heart preparation. | 1992 | Agents Actions Suppl. | pmid:1334351 |
| Alabaster VA et al. | UK-74,505, a novel and selective PAF antagonist, exhibits potent and long lasting activity in vivo. | 1991 | Agents Actions Suppl. | pmid:1793066 |
| Heuer HO | The effects of hetrazepine PAF antagonists in preclinical models of asthma. | 1991 | Agents Actions Suppl. | pmid:1793067 |
| Mazzoni L et al. | Changes in airway sensitivity to histamine are not necessarily paralleled by changed sensitivity to acetylcholine. | 1991 | Agents Actions Suppl. | pmid:1793069 |
| Soloviev A and Braquet P | The similarity in action of hypoxia and platelet-activating factor on smooth muscle cells of coronary arteries: possible explanation for hypoxic coronary spasm development. | 1995 | Agents Actions Suppl. | pmid:7717190 |
| Billah MM et al. | Sch 37370: a new drug combining antagonism of platelet-activating factor (PAF) with antagonism of histamine. | 1991 | Agents Actions Suppl. | pmid:1793070 |
| Saeed SA et al. | Inhibitory effect of oral ketotifen on ex vivo platelet activating factor-induced platelet aggregation. | 1991 | Agents Actions Suppl. | pmid:1793071 |
| Anderson GP and Fennessy MR | Lipoxygenase metabolites as mediators of platelet activating factor-induced increased airways responsiveness to histamine in the guinea-pig. | 1988 | Agents Actions Suppl. | pmid:3140616 |
| Hoshiko K et al. | Histamine(H1) antagonists and airway hyperreactivity in the guinea-pig. | 1991 | Agents Actions Suppl. | pmid:1686527 |
| Barnes PJ | New concepts in the pathogenesis of bronchial hyperresponsiveness. | 1987 | Agents Actions Suppl. | pmid:3314413 |
| Mustard JF et al. | Platelet activation--an overview. | 1987 | Agents Actions Suppl. | pmid:3314414 |
| Page CP and Spina D | The therapeutic relevance of PAF antagonists. | 1989 | Agents Actions Suppl. | pmid:2683635 |
| Mest HJ et al. | Effect of BN 52256 and other mediator antagonists on ouabain-induced ventricular fibrillation in sensitized guinea-pigs and on ischemia-induced fibrillation in rats. | 1992 | Agents Actions Suppl. | pmid:1632298 |
| Koltai M and Braquet PG | Involvement of PAF in atherogenesis. Brief review. | 1992 | Agents Actions Suppl. | pmid:1632308 |
| Page CP et al. | PAF-acether: a putative mediator of asthma and inflammation. | 1983 | Agents Actions Suppl. | pmid:6575595 |
| McMillan RM and Carter GW | Design and development of drugs. | 1991 | Agents Actions Suppl. | pmid:1664186 |
| Bult H et al. | Complement derived factors and prostacyclin formation by rabbit isolated peritoneum and cultured mesothelial cells. | 1984 | Agents Actions Suppl. | pmid:6382974 |
| Stenzel H et al. | Effect of the PAF-antagonist SRI 63-441 on the allergic reaction in awake dogs with natural asthma. | 1987 | Agents Actions Suppl. | pmid:2823582 |
| O'Flaherty JT and Wykle RL | Metabolic origin and fate of platelet-activating factor. | 1987 | Agents Actions Suppl. | pmid:2823583 |
| Etienne A et al. | Antithrombotic activity of BN 50341, a structurally new compound with anticalcic and PAF-antagonistic properties. | 1986 | Agents Actions Suppl. | pmid:3468781 |
| PAF, platelets and asthma. Proceedings of a meeting. September 7-9, 1986. | 1987 | Agents Actions Suppl. | pmid:3478993 | |
| Farr RS et al. | Platelet abnormalities in asthma--do they exist in humans? | 1987 | Agents Actions Suppl. | pmid:3478994 |
| Menz G et al. | Lack of PAF release in extrinsic asthma. | 1987 | Agents Actions Suppl. | pmid:3478995 |
| Northover AM | In vitro effects of PAF on venous endothelial cell actin disposition. | 1992 | Agents Actions | pmid:1509977 |
| Touvay C et al. | Inhibition of antigen-induced lung anaphylaxis in the guinea-pig by BN 52021 a new specific paf-acether receptor antagonist isolated from Ginkgo biloba. | 1986 | Agents Actions | pmid:3754380 |
| Benveniste J | Platelet-activating factor (PAF-acether): present status. | 1981 | Agents Actions | pmid:6176101 |
| Flower RJ | Background and discovery of lipocortins. | 1986 | Agents Actions | pmid:2938452 |
| Desai S and Barton R | Role of platelet activating factor in the pathogenesis of active and passive models of experimental allergic encephalomyelitis in the rat. | 1990 | Agents Actions | pmid:2285021 |
| de Bernardis E et al. | Protective effects of papaverine salicylate in mouse ear dermatitis and PAF-induced rat paw oedema. | 1994 | Agents Actions | pmid:7847181 |
| Boughton-Smith NK et al. | Actions of nitric oxide on the acute gastrointestinal damage induced by PAF in the rat. | 1992 | Agents Actions | pmid:1279960 |
| Cahill M et al. | Effect of des arginine9-bradykinin and other bradykinin fragments on the synthesis of prostacyclin and the binding of bradykinin by vascular cells in culture. | 1988 | Agents Actions | pmid:3051930 |
| Cunha FQ et al. | Failure of PAF-acether to induce in vivo neutrophil migration. | 1988 | Agents Actions | pmid:3055873 |
| Perret BA et al. | Binding of bovine factor VIII-coated colloidal gold particles to receptors on platelet membranes. | 1981 | Agents Actions | pmid:6803540 |
| Heller R et al. | S35b, a new phenylsulfonylfuroxan compound, inhibits thrombin-induced synthesis of platelet-activating factor and prostacyclin in human endothelial cells. | 1993 | Agents Actions | pmid:7517616 |
| Lecrubier C et al. | Study of platelet aggregation induced by platelet activating factor (PAF) after administration of ticlopidine or aspirin. | 1983 | Agents Actions | pmid:6858789 |
| Pirotzky E et al. | Vascular permeability induced by Paf-acether (platelet-activating factor) in the isolated perfused rat kidney. | 1985 | Agents Actions | pmid:4003192 |
| Page CP et al. | Platelet activating factor (Paf-acether) may account for late-onset reactions to allergen inhalation. | 1985 | Agents Actions | pmid:4003195 |
| Northover AM and Northover BJ | Lectin-induced increase in microvascular permeability to colloidal carbon in vitro may involve protein kinase C activation. | 1994 | Agents Actions | pmid:7942320 |
| Page CP et al. | Suppression of Paf-acether responses: an anti-inflammatory effect of anti-asthma drugs. | 1985 | Agents Actions | pmid:4003196 |
| Czarnetzki BM and Benveniste J | Effect of synthetic PAF-acether on human neutrophil function. | 1981 | Agents Actions | pmid:7041568 |
| Camussi G et al. | Neutropenia induced by platelet-activating factor (PAF-acether) released from neutrophils: the inhibitory effect of prostacyclin (PGI2). | 1981 | Agents Actions | pmid:7041569 |
| Swingle KF and Reiter MJ | Inhibition of Paf-acether-induced edema of the rat's paw. | 1986 | Agents Actions | pmid:2875631 |
| Tubaro E et al. | In vitro and in vivo impact of a new glycosphingolipid on neutrophils. | 1994 | Agents Actions | pmid:7879694 |
| Canale P et al. | TCV-309, a novel platelet activating factor antagonist, inhibits leukocyte accumulation and protects against splanchnic artery occlusion shock. | 1994 | Agents Actions | pmid:7879698 |